Nepafenac Compared to Placebo for Ocular Pain and Inflammation
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to demonstrate that Nepafenac Ophthalmic Suspension, 0.1% is
superior to Nepafenac Vehicle (placebo) for the prevention and treatment of ocular
inflammation and pain associated with cataract surgery in Chinese subjects.